Cargando…

Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure

BACKGROUND: Recent studies indicated that sodium glucose cotransporter (SGLT)2 inhibition increases levels of ketone bodies in the blood in patients with type 1 and 2 diabetes. Other studies suggested that in patients with chronic heart failure (CHF), increased myocardial oxygen demand can be provid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pietschner, R., Kolwelter, J., Bosch, A., Striepe, K., Jung, S., Kannenkeril, D., Ott, C., Schiffer, M., Achenbach, S., Schmieder, R. E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579532/ https://www.ncbi.nlm.nih.gov/pubmed/34753480 http://dx.doi.org/10.1186/s12933-021-01410-7

Ejemplares similares

Is vascular remodelling in patients with chronic heart failure exaggerated?
por: Pietschner, Robert, et al.
Publicado: (2022)

Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure
por: Bosch, Agnes, et al.
Publicado: (2023)

Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine
por: Ott, Christian, et al.
Publicado: (2021)

Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
por: Kolwelter, Julie, et al.
Publicado: (2021)

Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction
por: Jung, Susanne, et al.
Publicado: (2021)

The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial
por: Kolwelter, Julie, et al.
Publicado: (2022)

How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
por: Bosch, Agnes, et al.
Publicado: (2019)

Change of renal function after short-term use of cardioprotective agents in patients with type 2 diabetes is not accurately assessed by the change of estimated glomerular filtration rate: an observational study
por: Kolwelter, Julie, et al.
Publicado: (2022)

Determinants of arterial stiffness in patients with type 2 diabetes mellitus: a cross sectional analysis
por: Staef, Mawadah, et al.
Publicado: (2023)

Hypertrophic remodelling of retinal arterioles in patients with congestive heart failure
por: Jung, Susanne, et al.
Publicado: (2021)

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
por: Karg, M. V., et al.
Publicado: (2018)

Early vascular parameters in the micro- and macrocirculation in type 2 diabetes
por: Kannenkeril, Dennis, et al.
Publicado: (2018)

Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
por: Connelly, Kim A., et al.
Publicado: (2020)

Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers
por: Gessner, Arne, et al.
Publicado: (2022)

Ketone bodies and the heart
por: Papazafiropoulou, Athanasia K., et al.
Publicado: (2021)

The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)
por: Omar, Massar, et al.
Publicado: (2022)

The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
por: Lee, Hsiang-Chun, et al.
Publicado: (2019)

Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death
por: Hu, Zhaoyang, et al.
Publicado: (2021)

Empagliflozin—A New Chance for Patients with Chronic Heart Failure
por: Kowalska, Klaudia, et al.
Publicado: (2021)

Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients
por: Nielsen, Roni, et al.
Publicado: (2019)

Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial
por: Butler, Javed, et al.
Publicado: (2023)

Effects of Empagliflozin on Diuretics Reduction in Outpatient Heart Failure Patients
por: Kim, Soo-Jin, et al.
Publicado: (2022)

Hyperpolarized ketone body metabolism in the rat heart
por: Miller, Jack J., et al.
Publicado: (2018)

Coronary Sinus Neuropeptide Y Levels and Adverse Outcomes in Patients With Stable Chronic Heart Failure
por: Ajijola, Olujimi A., et al.
Publicado: (2020)

Ketone Body Metabolism in the Ischemic Heart
por: Kolwicz, Stephen C.
Publicado: (2021)

Retinal neurodegeneration in patients with end-stage renal disease assessed by spectral-domain optical coherence tomography
por: Jung, Susanne, et al.
Publicado: (2020)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
por: Li, Chenguang, et al.
Publicado: (2019)

Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
por: Biegus, Jan, et al.
Publicado: (2022)

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
por: Cherney, David ZI, et al.
Publicado: (2014)

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
por: Saucedo-Orozco, Huitzilihuitl, et al.
Publicado: (2022)

Empagliflozin prevents doxorubicin-induced myocardial dysfunction
por: Sabatino, Jolanda, et al.
Publicado: (2020)

Empagliflozin Reduces Interleukin-6 Levels in Patients with Heart Failure
por: Gotzmann, Michael, et al.
Publicado: (2023)

Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat
por: Park, Sin-Hee, et al.
Publicado: (2020)

Empagliflozin and the Prevention of Heart Failure: Will Reverse Translation Lead to New Paradigms for the Treatment of Heart Failure?
por: Mann, Douglas L., et al.
Publicado: (2017)

Mitochondrial Quality Control in Aging and Heart Failure: Influence of Ketone Bodies and Mitofusin-Stabilizing Peptides
por: Thai, Phung N., et al.
Publicado: (2019)

Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
por: Håkansson, Erik, et al.
Publicado: (2021)

Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
por: Butler, Javed, et al.
Publicado: (2022)

Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled( )
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Cost-effectiveness of empagliflozin for the treatment of heart failure: a systematic review
por: Liu, Jinyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9dmlj2gct1geoj9185vcfb7870